Roche achieves research success in the fight against obesity
Published: Wednesday, Jul 17th 2024, 07:50
Volver a Live Feed
Roche has a research success to report in the fight against obesity. However, the drug under investigation is still at a very early stage of research.
The product candidate in question is CT-996, which is taken once a day for the treatment of type 2 diabetes and obesity, as Roche announced on Wednesday. The active ingredient comes from the portfolio of the US company Carmot, which Roche acquired last December for a total of around 3 billion US dollars.
CT-996 belongs to the new class of lipid-lowering drugs, GLP-1 drugs, which are used to treat diabetes. As Roche now reports, CT-996 has achieved "significant results" in two sub-studies of the currently ongoing multi-part first clinical phase.
Specifically, the study results show that treatment with CT-996 led to a mean weight loss of 6.1 percent within four weeks in participants with obesity and without type 2 diabetes. According to the press release, this is a placebo-adjusted mean value.
According to Roche, obesity is one of the world's most pressing health problems, associated with numerous comorbidities such as type 2 diabetes, cardiovascular disease, liver disease and chronic kidney disease. It is estimated that more than four billion people - around 50 percent of the world's population - will be affected by obesity or overweight by 2035.
Second success story in a few days
Just a few days ago, Roche published data on its other obesity candidate CT-388, which was well received by analysts and investors.
With regard to CT-996, it is further stated that the drug was well tolerated. Many of the novel lipid-lowering agents are associated with considerable side effects.
©Keystone/SDA
Spanish 
English 
German 
French 
Arabic